Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15680232 | 0.83 | RAD52 (0.53) | KCNH2MCHR1HRH3LTA4H | |
| SCHEMBL15680617 | 0.81 | CNR2 (0.48) | KCNH2MCHR1HRH3LTA4HSIGMAR1 | |
| SCHEMBL15680267 | 0.78 | KCNH2 (0.54) | KCNH2MCHR1HRH3LTA4HACHE | |
| SCHEMBL14842971 | 0.78 | DRD2 (0.44) | KCNH2MCHR1HRH3LTA4HDRD2 | |
| SCHEMBL17191999 | 0.78 | HRH3 (0.49) | KCNH2MCHR1HRH3LTA4H | |
| SCHEMBL15680279 | 0.77 | CACNA1G (0.51) | KCNH2MCHR1HRH3LTA4HSIGMAR1 | |
| SCHEMBL15680312 | 0.76 | KCNH2 (0.43) | KCNH2MCHR1HRH3LTA4HSIGMAR1 | |
| SCHEMBL18467722 | 0.75 | DRD2 (0.44) | KCNH2MCHR1HRH3LTA4HSIGMAR1 | |
| SCHEMBL14854353 | 0.74 | MCHR1 (0.46) | KCNH2MCHR1HRH3LTA4HSIGMAR1 | |
| SCHEMBL15680542 | 0.74 | KCNH2 (0.49) | KCNH2MCHR1HRH3LTA4HSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2017-10-05 | — | — | US | disclosed |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LTD (GB) | 2015-10-22 | — | — | US | disclosed |
| WO-2014068388-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2014-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281532-A1 | 2 SUBSTITUTED CEPHEM COMPOUNDS | CEP170, CES2, CMBL | KCNH2 2246/4885MCHR1 4370/4885HRH3 3855/4885 |
| US-20150299223-A1 | 2-SUBSTITUTED CEPHEM COMPOUNDS | CEP170, ABL1, CEPT1 | KCNH2 178/4885MCHR1 2741/4885HRH3 787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.